i
Important informations
Instagram
Portal
Donate now

Our researchers

Aucun résultat

Dr. Mark J. Eisenberg

Mark J. Eisenberg, MD, MPH

Clinical Epidemiology

Cardiology, Cardiovascular disease prevention, Clinical trials, E-cigarettes, Epidemiology, Meta-analysis, Smoking cessation, Systematic review
  • Senior Investigator, Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research
  • Director, Cardiovascular Health Services Research Group, Jewish General Hospital
  • Director, Cardiac Catheterization Laboratory, Jewish General Hospital
  • James McGill Professor of Medicine, McGill University

Contact details

(514) 340-8222 ext. 23564
mark.eisenberg@mcgill.ca

Assistant contact details

  • Tabitha Finch,
    Clinical Research Coordinator Team Leader
    (514) 340-8222 ext. 23240
    Tabitha.finch@ladydavis.ca

Snapshot

Dr. Mark J. Eisenberg’s research focuses on the primary and secondary prevention of cardiovascular disease, with topics ranging from interventional cardiology to broad public health issues such as smoking and obesity. His latest randomized controlled trial (RCT), the Aggressive Smoking Cessation Therapy Among People at Elevated Cardiovascular Risk (ASAP) Trial, is a multi-centre clinical trial that assesses the efficacy, safety, and tolerability of aggressive smoking cessation therapy among people at elevated cardiovascular risk. A total of 798 participants are being randomized 1:1 to: (1) varenicline and nicotine e-cigarettes (aggressive smoking cessation therapy), or (2) varenicline alone for 12 weeks, with follow-up of 52 weeks. The ASAP Trial design builds off of his most recently completed RCT, E3 (see citations under ‘Recent Publications’), the results of which suggest that nicotine e-cigarettes are moderately efficacious for smoking cessation.

Dr. Mark J. Eisenberg is a James McGill Professor of Medicine at McGill University and a Staff Cardiologist at the Jewish General Hospital. He is an Associate Member of the McGill Department of Epidemiology, Biostatistics, and Occupational Health. In addition to his clinical responsibilities, Dr. Eisenberg is Director of the Cardiovascular Health Services Research Group of the Jewish General Hospital and a Senior Investigator at the Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research.

Dr. Eisenberg was born in Rochester, New York. He completed a BA in Chemistry in 1980 at Cornell University, followed by an MD at the University of Rochester. After completing his MD, Dr. Eisenberg did a residency in internal medicine at McGill University, a Masters of Public Health at Harvard University, a research fellowship in echocardiography and epidemiology and a cardiology fellowship at the University of California in San Francisco. In 1995, Dr. Eisenberg completed an interventional cardiology fellowship at the Cleveland Clinic.

In 2008-2009, Dr. Eisenberg spent a year in Israel as a visiting professor in the Department of Human Metabolism and Nutrition at the Joseph H. and Belle R. Braun Hebrew University, Hadassah School of Public Health and Community Medicine. During this sabbatical, he also completed an International Master’s of Health Leadership at McGill University.

Dr. Eisenberg is married and has five children. He is fluent in English, French, and Hebrew.

Read more

Important Links :

See Dr. Mark J. Eisenberg's publications on PubMed

Major Research Activities

Over the course of his career, Dr. Mark J. Eisenberg has published over 300 articles in peer-reviewed journals and participated in multiple collaborative works.

 

His research team is examining the use and effectiveness of various smoking cessation pharmacotherapies with several randomized controlled trials.

  • The Zyban as an Effective Smoking Cessation Aid (ZESCA) trial compared the efficacy of bupropion (Zyban) to that of a placebo as a means of reducing smoking rates in patients following an enzyme-positive acute coronary syndrome (ACS).
  • The evaluation of varenicline (Champix™) in smoking cessation for patients post-acute coronary syndrome (EVITA) trial examined the efficacy and safety of varenicline for smoking cessation post-ACS.
  • The CIHR-funded Evaluating the Efficacy of E-Cigarette use for Smoking Cessation (E3) trial assessed the efficacy of nicotine and non-nicotine e-cigarettes for smoking cessation in the general population of smokers motivated to quit.
  • Eisenberg’s current CIHR-funded trial, titled Aggressive Smoking Cessation Therapy Among People at Elevated Cardiovascular Risk (ASAP), aims to determine the efficacy of combining varenicline and nicotine e-cigarettes for increased smoking abstinence among people at elevated cardiovascular risk.
  • Eisenberg’s research team also performs systematic reviews and meta-analyses. Recent publications concern the regulation, ethics, and efficacy of e-cigarettes for smoking cessation, impaired driving and cannabis use, and revascularization in patients with ST-segment elevation myocardial infarction and multivessel coronary disease.

In addition, Dr. Eisenberg has authored four books, the links for which are listed under the “Important Links” section of this page.

Recent Publications and References

LDI logo
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.